Chon­dr­i­al bags a $22M A round for mi­to­chon­dr­i­al R&D; Ari­ad filed mar­ket­ing app for briga­tinib

• Deer­field has tak­en the lead on a $22.6 mil­lion Se­ries A for Chon­dr­i­al Ther­a­peu­tics, a Bala Cyn­wyd, PA-based biotech with a fo­cus on rare mi­to­chon­dr­i­al dis­eases. The biotech in-li­censed CTI-1601 for the treat­ment of Friedre­ich’s Atax­ia from In­di­ana Uni­ver­si­ty Re­search and Tech­nol­o­gy Corp. and Wake For­est Uni­ver­si­ty Health Sci­ences. Ca­r­ole Ben-Mai­mon was named CEO.

• Ari­ad says that it has sub­mit­ted a mar­ket­ing ap­pli­ca­tion for briga­tinib with the EMA. The can­cer drug, which fig­ured promi­nent­ly in Take­da’s $5.2 bil­lion buy­out deal, is al­ready un­der re­view at the FDA, where it faces an April 29 PDU­FA date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.